
Alpine A290 Rallye Is an Electric Hot Hatch You Can Take Racing
Along with 215 hp, the front-wheel-drive EV features better brakes, an FIA-certified roll cage, and a revised suspension.
The factory-prepped A290 Rallye also has a hydraulic handbrake for executing tight turns; too bad it's not sold in the United States.
Alpine's roots in rally racing can be traced all the way back to 1955 when the French automaker was founded by Jean Rédélé. The Alpine A106 helped put the brand on the motorsports map, and the subsequent A110 cemented its legacy in the 1960s and '70s. Now, Alpine is catering to the next generation of home-grown racers with the A290 Rallye, a factory-prepped electric race car that customers can buy.
Based on the Alpine A290 hatchback, the recently revealed Rallye version shares the same platform and powertrain. The latter includes a front-mounted electric motor that makes 215 horsepower and 221 pound-feet of torque; a ZF-sourced limited-slip differential transmits that power to the front axle. White-painted 18-inch EVO Corse wheels are bolted to each corner, and they're wrapped with Michelin Pilot Sport A tires that are only road-legal in Europe.
Alpine
Alpina
The Alpine A290 Rallye also wears a shade of the brand's hallmark blue paint, and it features a distinctive livery that's predominantly white, albeit with red and black accents. Along with glossy black fender flares, the hatchback's hood is matte black and matches the roof, which features a cute little air scoop. The regular A290—itself based on the Renault 5—has handsome proportions, with its muscular boxed fenders and front lights that incorporate X-shaped elements. That all carries over to the race car, which also benefits from upgrades that make it more than just an appearance package.
Working with its Viry-Châtillon teams, Alpine and Co. transformed the EV hatch into an FIA-compliant racer. That means it has a welded roll cage and Sabelt racing seats, not to mention a hydraulic handbrake to help the driver quickly navigate hairpin turns. The Rallye's roster of upgrades also includes a reworked suspension with ALP Racing dampers as well as better brakes, specifically a pair of six-piston monoblock front calipers that clamp 13.8-inch rotors. Alpine says the cars have a race-specific ABS calibration too. Despite missing an internal-combustion engine, the electric A290 racer makes fake sounds that are associated with its accelerator position and speed.
Alpine
If you haven't noticed, Alpine doesn't currently sell new cars in North America, and the A290 Rallye is no different. Our friends across the pond can expect to pay the equivalent of about $70K for the factory-built race car. Alpine said it's planning to organize a single rally event somewhere in France before the end of the year for a limited number of customers to participate. Of course, the A290 racer will be able to independently compete in spec races and open competitions.
Eric Stafford
Managing Editor, News
Eric Stafford's automobile addiction began before he could walk, and it has fueled his passion to write news, reviews, and more for Car and Driver since 2016. His aspiration growing up was to become a millionaire with a Jay Leno–like car collection. Apparently, getting rich is harder than social-media influencers make it seem, so he avoided financial success entirely to become an automotive journalist and drive new cars for a living. After earning a journalism degree at Central Michigan University and working at a daily newspaper, the years of basically burning money on failed project cars and lemon-flavored jalopies finally paid off when Car and Driver hired him. His garage currently includes a 2010 Acura RDX, a manual '97 Chevy Camaro Z/28, and a '90 Honda CRX Si. Read full bio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
NIO's Firefly Brand Uses HERE Technologies to Power Smart, Connected EV Journeys
NIO Inc. (NYSE:NIO) is among the 12 Best EV Charging Stocks to Buy According to Hedge Funds. Firefly, a sub-brand of NIO Inc. (NYSE:NIO), has teamed up with HERE Technologies to incorporate innovative location services and superior map data into its intelligent electric cars. Firefly promises to enhance connected navigation, driver assistance systems, and conformity to EU Intelligent Speed Assistance rules by integrating HERE's global maps and real-time traffic updates. Furthermore, the integration makes use of HERE and Telenav 's partnership for in-car navigation. A cutting-edge electric vehicle being charged in a city street as the sun sets. Chris Chen, VP of NIO Inc. (NYSE:NIO) Global Business Development, stressed the need for HERE's global experience in satisfying international safety requirements as Firefly develops in Europe. Firefly was created for urban transportation to make high-end EV features more widely available. NIO Inc. (NYSE:NIO) displayed its explosive expansion in Q1 2025 by delivering over 42,094 vehicles, a 40.1% increase year over year. Deon Newman, SVP of HERE, pointed out the company's commitment to providing Chinese EV brands with AI-powered location technology as they expand abroad, notably in Europe. While we acknowledge the potential of NIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Daimler Truck slashes key profit forecast on North America weakness
FRANKFURT (Reuters) -Daimler Truck, one of the world's biggest truckmakers, on Thursday slashed a key profit forecast for 2025 due to "continuous market weakness in North America", the latest warning from industry as U.S. President Donald Trump imposes tariffs on imports. The German company now expects adjusted earnings before interest and taxes (EBIT) in a range of 3.6 billion euros to 4.1 billion euros ($4.1 billion to $4.7 billion), compared with 4.7 billion euros reported for 2024. That would mark a drop of as much as 23%. The company previously forecast that adjusted EBIT for 2025 would be just 5% lower, and could even rise 5%. "After a strong first half in North America, recent months have shown a clear slowdown in order levels, reflecting ongoing market uncertainty. In response, we have adjusted our capacity and lowered our market guidance and volume outlook," said Chief Financial Officer Eva Scherer. ($1 = 0.8755 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Dupixent sales spur Sanofi growth, but profits fall short
Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported lower-than-expected profits after outlaying money to develop new treatments. Dupixent generated sales of €3.8bn ($4.35bn) for the company in the quarter, growing 21.1% over the same period in 2024. Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent's success pushed Sanofi's total net sales to €9.9bn, up 10% at constant exchange rate (CER). The French drugmaker said it expects annual sales growth in the high single-digits at constant currency rates, compared to a previous forecast of mid- to high-single-digit growth. In a conference call on 31 July, chief financial officer François-Xavier Roger said that whilst tariffs were not modelled into the guidance, little impact is expected on financials in 2025. Sanofi CEO Paul Hudson said: 'Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses.' Sanofi confirmed it hopes to complete a €5bn share buyback programme in 2025, adding that around 80% has been repurchased to date. However, despite progressing its ownership control, earnings per share rose 1.9% to €1.59, lower than the €1.65 analysts estimated. Shares in Sanofi fell 1% at market open to €84.70 on the Paris exchange following the Q2 report posting, despite the strong growth for Dupixent. The profit miss was primarily due to an increase in research and development (R&D) expenses. Sanofi invested €1.9bn into the department as it seeks new drugs and vaccines to succeed Dupixent, wary of its outlook becoming too reliant on sales for the product. The R&D spending represented a 17.7% jump compared to Q2 last year. Sanofi also looked beyond in-house development in efforts to bolster its pipeline – the pharma company has had a busy July in the acquisition space. In July, the drugmaker concluded its buyout of Blueprint Medicines for $9.1bn and agreed to acquire vaccine developer Vicebio for an upfront payment of $1.5bn. In addition, Sanofi bought Dren Bio's bispecific antibody for $1.9bn in March 2025 and made a push into Alzheimer's with a $470m deal for Vigil Neuroscience in May. Despite M&A buzz, Sanofi shares have declined this year in comparison to other big pharma companies. This has been primarily due to vaccine regulation uncertainty in the US. Alongside the company's pipeline diversification strategy, Duxipent looks set to supply a healthy financial outlook for Sanofi. Analysis by GlobalData forecasts sales of €23.8bn by 2031. This is based on rising uptake for the drug and further indications it's set to gain approval in. GlobalData analysts said Dupixent addressed a biologics gap in the COPD market at the time of approval. "Dupixent sales spur Sanofi growth, but profits fall short" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio